Novartis and Eli Lilly are exiting the neurological disease therapy developer in an acquisition that will involve $52.5m upfront and up to $250m in milestone payments.

Biopharmaceutical company Jazz Pharmaceuticals acquired Cavion, a US-based neurological disease drug developer backed by pharmaceutical firms Novartis and Eli Lilly, on Monday for up to $313m. The company‚Äôs shareholders received $52.5m upfront and are in line for up to $250m more in the form of clinical, regulatory and commercial milestone payments. It is merging with…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.